See the DrugPatentWatch profile for tigecycline

Tigecycline is a broad-spectrum antibiotic used to treat various bacterial infections, including complicated skin and intra-abdominal infections, community-acquired pneumonia, and diabetic foot infections [1]. Its breakdown, or pharmacokinetics, plays a significant role in determining the ideal dosage intervals.

Tigecycline is primarily metabolized by hydrolysis in the liver, with a minor contribution from other organs [2]. This metabolic pathway results in the formation of various metabolites, which are then excreted through the biliary system and urine [2]. The drug's long half-life (27 hours) allows for once- or twice-daily dosing, depending on the severity of the infection and the patient's renal function [1][2].

The breakdown of tigecycline is not significantly influenced by factors such as age, sex, or ethnicity [1]. However, renal impairment can lead to an increase in tigecycline exposure and a potential risk of accumulation [1]. In such cases, a reduced dosage or extended interval between doses may be necessary [1].

In conclusion, the breakdown of tigecycline plays a crucial role in determining the ideal dosage intervals. The drug's long half-life and primary metabolic pathway allow for once- or twice-daily dosing, but renal impairment may necessitate adjustments to the regimen [1][2].

Sources:
[1] FDA. (2010). Tygacil (tigecycline) tablets for oral use. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021837s010lbl.pdf
[2] DrugPatentWatch.com. (n.d.). Tigecycline. Retrieved from https://www.drugpatentwatch.com/drugs/tigecycline